RSS
|
Login
|
Register
Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Issue Archive
Events
Awards
Webcasts
Surveys
Directories
PMD
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
Antidote Articles
Antidote
Marc Siegel, MD
July 01, 2008
Chantix is taking a real beating this month.
Antidote
Marc Siegel, MD
June 01, 2008
I promise you that heparin is a perfectly good drug, though if you have been reading the newspapers lately, you wouldn't think so.
Antidote
Marc Siegel, MD
May 01, 2008
Even if I had another topic planned, how could I not write this month about Zetia?
Antidote
Marc Siegel, MD
April 01, 2008
I have an expression that I like to use when describing a drug's fall from graceāI call it going from panacea to panic.
Antidote
Marc Siegel, MD
March 01, 2008
Researchers at the National Institutes of Health released findings of the ACCORD study which appeared to show that driving blood sugar to low levels in diabetics leads to an increased rate of dying.
Antidote
Marc Siegel, MD
February 01, 2008
Now that we are in a presidential election year, much attention has been directed toward the question of how to extend healthcare to more people.
Antidote
Marc Siegel, MD
January 01, 2008
In past columns I have defended the commonly used sleeping pill Ambien.
Antidote
Marc Siegel, MD
December 01, 2007
We all like a good mystery, so we tend to overreact and over-personalize infectious threats that are truly remote.
Antidote
Marc Siegel, MD
November 01, 2007
I think it's time I devoted a column to a phenomenon known as forced substitution.
Antidote
Marc Siegel, MD
October 01, 2007
I never believed it was entirely fair that Eli Lilly was the target of vicious attacks regarding its anti-psychotic drug, Zyprexa.
« Previous
Next »
Most Popular
PhRMA Code cracks down on gifts to docs
Pfizer's Saxton: healthcare professionals must lead CME
More docs using mobile devices: Manhattan Research
Rx drug word-of-mouth occurs largely offline: study
Massachusetts dumps gift ban, punts on data
Chairman of LyonHeart announces retirement
Novartis has eyes for Alcon
GSK downsizes in consumer healthcare consolidation
FDA consolidates drug application responses
MM&M Awards finalists unveiled next week
Most Emailed
Pfizer sacks commercial support of CME
PhRMA Code cracks down on gifts to docs
Fed up Sermo docs draft manifesto
More docs using mobile devices: Manhattan Research
Pfizer's Saxton: healthcare professionals must lead CME
WebMD shares down on news of declining ads
Eli Lilly most esteemed pharma company for psychiatrists: Verispan
Rx drug word-of-mouth occurs largely offline: study
Senator slaps GSK med ed in letter to ACCME
Spot cable shop woos pharma advertisers with VOD channel
Most Recent
Teva in $7.4 billion Barr buy
GSK downsizes in consumer healthcare consolidation
Massachusetts dumps gift ban, punts on data
Pfizer's Saxton: healthcare professionals must lead CME
MM&M Awards finalists unveiled next week
Rx drug word-of-mouth occurs largely offline: study
PhRMA Code cracks down on gifts to docs
FDA consolidates drug application responses
More docs using mobile devices: Manhattan Research
Novartis has eyes for Alcon
Popular Tags
Advertising
Agency
Approval
Awards
Biotech
Business
Continuing medical education (CME)
Digital
Direct marketing
Direct to consumer (DTC)
FDA
Generic
Government
Legal
Marketing & Communications
Marketing Research
Media
Online
Over the counter (OTC)
Pharmaceutical
Professional
Promotion
Regulatory
Sales force
Suppliers & Vendors
Home
|
News
|
Features
|
Events
|
Surveys
|
Lists
|
Directories
|
Jobs
|
About Us
|
Contact Us
|
Subscribe
|
Newsletters
|
PMD
|
Advertise
|
Editorial Advisory Board
|
RSS